𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Botulinum toxin type-a in therapy of patients with anismus

✍ Scribed by Y. Ron; Y. Avni; A. Lukovetski; J. Wardi; D. Geva; S. Birkenfeld; Z. Halpern

Publisher
Springer
Year
2001
Tongue
English
Weight
550 KB
Volume
44
Category
Article
ISSN
0012-3706

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Botulinum toxin antibody type A titres a
Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy
✍ Dirk Dressler; Hans Bigalke πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 145 KB

## Abstract In some patients, therapy with botulinum toxin type A (BT‐A) becomes ineffective due to formation of antibodies (BT‐A‐AB). The time course of BT‐A‐AB titres after cessation of BT‐A therapy was quantitatively studied to determine whether and when they might drop. Thirteen patients (eight

Use of botulinum toxin type F injections
Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A
✍ Dr. Paul E. Greene; Stanley Fahn πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 492 KB

## Abstract Fifteen patients with torticollis who had been treated with repeated injections of botulinum toxin type A (botox A) developed antibodies to the toxin. This resulted in loss of benefit in the 13 patients who had improved with botox A injections and failure to develop muscle atrophy after

Development of resistance to botulinum t
Development of resistance to botulinum toxin type A in patients with torticollis
✍ Dr. Paul Greene; Stanley Fahn; Beverly Diamond πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 453 KB

## Abstract Between 1984 and 1992, 559 patients with torticollis were treated with botulinum toxin type A (btx) injections. Twenty‐four of these 559 patients (4.3%) had serological evidence of antibodies to btx by mouse neutralization assay. Some of the 559 patients had only one or two injection se

Secondary nonresponsiveness to botulinum
Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia
✍ Charles H. Adler; Stewart A. Factor; Mitchell Brin; Kapil D. Sethi πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 77 KB

## Abstract Intramuscular injection of botulinum toxin type A is the treatment of choice for most cases of oromandibular dystonia. We report on five patients with oromandibular dystonia that developed secondary nonresponsiveness to botulinum toxin type A following multiple injections over a 6‐year